Moderate-to-severe plaque psoriasis is a chronic, immune-mediated disorder characterized by widespread cutaneous inflammation and prominent systemic manifestations. Clinicians increasingly recognize that metabolic comorbidities significantly alter therapeutic trajectories and long-term patient outcomes. In particular, the role of serum uric acid in psoriasis has garnered substantial attention because hyperuricemia frequently coexists with psoriatic disease. Emerging multicenter evidence indicates that elevated uric acid levels do not merely reflect metabolic dysfunction; they also directly influence clinical response to biologic therapies targeting interleukin-17A, such as ixekizumab.

Understanding Serum Uric Acid in Psoriasis and Systemic Inflammation

Psoriasis involves rapid keratinocyte turnover and chronic immune activation driven primarily by the interleukin-23 and interleukin-17 signaling axis. Consequently, accelerated epidermal cell breakdown releases purine nucleotides, leading to heightened uric acid synthesis. Beyond simple cellular turnover, shared cardiometabolic pathways link psoriatic disease to obesity, non-alcoholic fatty liver disease, hypertension, and dyslipidemia. Serum uric acid functions as both an antioxidant in extracellular spaces and a potent pro-inflammatory danger signal within cellular compartments. When uric acid accumulates, it activates intracellular stress pathways and stimulates cytokine cascades, amplifying systemic vascular and tissue inflammation. Therefore, hyperuricemia serves as an active metabolic modulator of inflammatory severity rather than an innocent bystander. Clinicians managing refractory plaque psoriasis must recognize that elevated uric acid exacerbates underlying immune dysregulation. As a result, evaluating baseline urate concentrations provides critical insights into systemic disease burden and potential therapeutic challenges.

Multicenter Cohort Design and Methodological Framework

To investigate the clinical impact of hyperuricemia, investigators conducted a rigorous prospective cohort study across 26 dermatology centers in China. The study enrolled 390 adult patients presenting with moderate-to-severe plaque psoriasis between August 2020 and May 2022. All participants received standard induction and maintenance regimens of ixekizumab, receiving an initial loading dose of 160 mg at week 0, followed by 80 mg subcutaneously every two weeks through week 12. Investigators measured baseline serum uric acid concentrations to categorize participants based on the presence of hyperuricemia. Furthermore, researchers utilized the validated Psoriasis Area and Severity Index to evaluate objective cutaneous improvement at defined intervals. To assess complex nonlinear associations, the authors employed restricted cubic spline analyses alongside multivariate logistic regression models adjusting for potential confounders. Additionally, the researchers performed advanced proximity extension assays via Olink Proteomics to measure 92 distinct plasma inflammatory proteins, uncovering detailed mechanistic links between metabolic status and systemic immune profiles.

Treatment Outcomes: How Hyperuricemia Blunts Ixekizumab Efficacy

The clinical results demonstrated a striking divergence in therapeutic response between normouricemic individuals and those presenting with elevated serum urate levels. Patients with hyperuricemia demonstrated a markedly higher baseline prevalence of central obesity, hyperlipidemia, and hyperglycemia. Following 12 weeks of continuous ixekizumab administration, patients with hyperuricemia achieved significantly poorer cutaneous clearance across all clinical endpoints. Specifically, adjusted logistic regression models demonstrated that hyperuricemic patients had a substantially lower likelihood of achieving a 75% reduction in baseline severity scores. More importantly, stringent therapeutic goals exhibited even steeper declines; these individuals faced significantly reduced odds of reaching a 90% reduction and complete cutaneous clearance. Restricted cubic spline modeling confirmed a continuous inverse relationship, showing that higher baseline urate concentrations progressively degraded biologic efficacy. Consequently, hyperuricemia acts as an independent negative predictor for rapid skin clearance during targeted interleukin-17A inhibition.

Proteomic Profiling and Systemic Inflammatory Cascades

High-throughput proteomic profiling revealed intricate molecular connections between elevated urate concentrations and circulating immune mediators. The Olink Proteomics platform identified statistically significant correlations between serum uric acid levels and 26 distinct circulating inflammatory proteins. Biological pathway enrichment analyses demonstrated that these elevated proteins clustered heavily around tumor necrosis factor signaling cascades, lymphocyte activation pathways, and broad cytokine-mediated activities. Elevated uric acid appears to prime circulating mononuclear cells, sustaining background systemic inflammation despite potent targeted inhibition of interleukin-17A. Furthermore, these proteomic signatures suggest that hyperuricemia fosters an inflammatory microenvironment that partially bypasses single-cytokine blockade. The persistence of alternative pro-inflammatory signals explains why patients with high urate levels experience blunted clinical responses. Therefore, comprehensive proteomic mapping underscores the vital biological interplay between purine metabolism, innate immune activation, and targeted biologic therapeutics.

Clinical Implications for Comprehensive Dermatologic Care

These findings carry immediate, actionable relevance for contemporary clinical practice in dermatology and internal medicine. Clinicians should routinely screen serum uric acid levels alongside comprehensive lipid and glycemic panels in patients initiating biologic therapy. Because hyperuricemia heralds reduced biologic responsiveness, identifying elevated urate enables early risk stratification and closer monitoring during induction phases. Moreover, addressing hyperuricemia requires proactive, multidisciplinary collaboration between dermatologists, rheumatologists, and primary care physicians. Structured lifestyle modifications, including weight management, dietary purine reduction, and regular aerobic exercise, provide foundational benefits for metabolic health and inflammatory control. In selected patients with concomitant gout or severe asymptomatic hyperuricemia, targeted urate-lowering therapy may restore metabolic balance and optimize overall responsiveness. Ultimately, integrating metabolic management into standard psoriasis protocols ensures more holistic care, improving cutaneous clearance, cardiovascular health, and long-term quality of life.

Frequently Asked Questions

How does serum uric acid in psoriasis affect ixekizumab treatment response?

Elevated serum uric acid in psoriasis significantly reduces the likelihood of achieving clear or almost clear skin during ixekizumab therapy. Research demonstrates that hyperuricemic patients have lower odds of reaching PASI 75, PASI 90, and PASI 100 clearance benchmarks after 12 weeks. High uric acid levels sustain background inflammatory signaling, which diminishes the overall clinical effectiveness of targeted interleukin-17A inhibition.

Why is hyperuricemia common among patients with moderate-to-severe psoriasis?

Hyperuricemia occurs frequently in moderate-to-severe psoriasis due to accelerated epidermal cell proliferation and turnover, which increases endogenous purine catabolism and uric acid production. In addition, psoriasis strongly correlates with metabolic syndrome components, including obesity and insulin resistance, which reduce renal urate excretion. Consequently, systemic immune activation and shared cardiometabolic abnormalities synergistically drive elevated uric acid levels.

Should dermatologists routinely test serum uric acid in psoriasis patients?

Dermatologists should routinely assess serum uric acid levels before initiating biologic therapy in moderate-to-severe psoriasis. Baseline testing identifies coexisting cardiometabolic risk factors and stratifies patients who may experience sub-optimal treatment responses. Monitoring urate enables clinicians to implement multidisciplinary interventions, including dietary counseling, lifestyle changes, or urate-lowering therapy, thereby enhancing therapeutic outcomes and long-term systemic health.

Disclaimer: This content is for informational and educational purposes only and should not be considered medical advice. Always consult a qualified healthcare professional regarding any medical condition or treatment decisions. Medical knowledge is constantly evolving; therefore, readers must independently verify all information, doses, and protocols against standard reference materials. The authors and publishers assume no responsibility or liability for any clinical decisions made based on this content. Refer to the latest local and national guidelines for clinical practice.

References

1. Jiang Y et al. Association of serum uric acid with circulating inflammatory proteins and treatment response to ixekizumab in patients with psoriasis: A multicenter prospective cohort study in China. Chin Med J (Engl). 2026 Aug 24. doi: 10.1097/CM9.0000000000004261. PMID: 42637676.


2. Gisondi P, Fostini AC, Fossà I, Girolomoni G, Targher G. Psoriasis and metabolic syndrome: implications for the management and treatment of patients. J Eur Acad Dermatol Venereol. 2018;32(5):734-744. doi:10.1111/jdv.14674.


3. Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020;323(19):1945-1960. doi:10.1001/jama.2020.4006.